

**Goat Anti-Factor XIIIa (703-717) Antibody**  
**Peptide-affinity purified goat antibody**  
**Catalog # AF1395a****Specification**

---

**Goat Anti-Factor XIIIa (703-717) Antibody - Product Information**

Application	WB
Primary Accession	<a href="#">P00488</a>
Other Accession	<a href="#">NP_000120</a> , <a href="#">2162</a>
Reactivity	Human
Predicted	Mouse
Host	Goat
Clonality	Polyclonal
Concentration	100ug/200ul
Isotype	IgG
Calculated MW	83268

**Goat Anti-Factor XIIIa (703-717) Antibody - Additional Information****Gene ID** 2162**Other Names**

Coagulation factor XIII A chain, Coagulation factor XIIIa, 2.3.2.13, Protein-glutamine gamma-glutamyltransferase A chain, Transglutaminase A chain, F13A1, F13A

**Format**

0.5 mg IgG/ml in Tris saline (20mM Tris pH7.3, 150mM NaCl), 0.02% sodium azide, with 0.5% bovine serum albumin

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

Goat Anti-Factor XIIIa (703-717) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

**Goat Anti-Factor XIIIa (703-717) Antibody - Protein Information****Name** F13A1**Synonyms** F13A**Function**

Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl- epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot. Also cross-link alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin.

**Cellular Location**

Cytoplasm. Secreted. Note=Secreted into the blood plasma. Cytoplasmic in most tissues, but also secreted in the blood plasma

**Goat Anti-Factor XIIIa (703-717) Antibody - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**Goat Anti-Factor XIIIa (703-717) Antibody - Images**

AF1395a (0.1 µg/ml) staining of Human Placenta lysate (35 µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

**Goat Anti-Factor XIIIa (703-717) Antibody - Background**

This gene encodes the coagulation factor XIII A subunit. Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. It also crosslinks alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion.

**Goat Anti-Factor XIIIa (703-717) Antibody - References**

A genetic association study of maternal and fetal candidate genes that predispose to preterm

prelabor rupture of membranes (PROM). Romero R, et al. Am J Obstet Gynecol, 2010 Jul 29. PMID 20673868.

Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations in two population-based cleft studies from Scandinavia. Jugessur A, et al. PLoS One, 2010 Jul 9. PMID 20634891.

Variation at the NFATC2 Locus Increases the Risk of Thiazolinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.

Allele-allele interaction within the F13A1 gene: a risk factor for ischaemic heart disease in Spanish population. Carreras-Torres R, et al. Thromb Res, 2010 Sep. PMID 20553949.

Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders. Antón AI, et al. Ann Hematol, 2010 Nov. PMID 20532885.